| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Departments of Surgery (MWO, RBN, RF, BC, CM, TNP, KL, HFS, DST), Medicine (HH, MM, PJ, KM), and Radiation Oncology (CL, MSA), Duke University Medical Center, Durham, North Carolina.
Correspondence: Address correspondence and reprint requests to: Douglas S. Tyler, MD, Department of Surgery, Duke University Medical Center, DUMC Box 3118, Durham, NC 27710; Fax: 919-681-8701; E-mail: tyler002{at}acpub.duke.edu
Background: Up to 30% of patients with locally advanced rectal cancer have a complete clinical or pathologic response to neoadjuvant chemoradiation. This study analyzes complete clinical and pathologic responders among a large group of rectal cancer patients treated with neoadjuvant chemoradiation.
Methods: From 1987 to 2000, 141 consecutive patients with biopsy-proven, locally advanced rectal cancer were treated with preoperative 5-fluorouracil-based chemotherapy and radiation. Clinical restaging after treatment consisted of proctoscopic examination and often computed tomography scan. One hundred forty patients then underwent operative resection, with results tracked in a database. Standard statistical methods were used to examine the outcomes of those patients with complete clinical or pathologic responses.
Results: No demographic differences were detected between either clinical complete and clinical partial responders or pathologic complete and pathologic partial responders. The positive predictive value of clinical restaging was 60%, and accuracy was 82%. By use of the Kaplan-Meier life table analysis, clinical complete responders had no advantage in local recurrence, disease-free survival, or overall survival rates when compared with clinical partial responders. Pathologic complete responders also had no recurrence or survival advantage when compared with pathologic partial responders. Of the 34 pathologic T0 tumors, 4 (13%) had lymph node metastases.
Conclusions: Clinical assessment of complete response to neoadjuvant chemoradiation is unreliable. Micrometastatic disease persists in a proportion of patients despite pathologic complete response. Observation or local excision for patients thought to be complete responders should be undertaken with caution.
Key Words: Rectal cancer • Neoadjuvant chemoradiation • Complete response • Total mesorectal excision
This article has been cited by other articles:
 |
|
 |
|
  J. C. Mansour, L. Tang, M. Shah, D. Bentrem, D. S. Klimstra, M. Gonen, D. P. Kelsen, M. F. Brennan, and D. G. Coit Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer? Ann. Surg. Oncol., December 1, 2007; 14(12): 3412 - 3418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-J. Kuo, M.-C. Liu, J. J.-M. Jian, C.-F. Horng, T.-I Cheng, C.-M. Chen, W.-T. Fang, and Y.-L. Chung Is Final TNM Staging A Predictor for Survival in Locally Advanced Rectal Cancer after Preoperative Chemoradiation Therapy? Ann. Surg. Oncol., October 1, 2007; 14(10): 2766 - 2772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Han and S. Galandiuk Induction Chemoradiation for Rectal Cancer Arch Surg, December 1, 2006; 141(12): 1246 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Stipa, D. B. Chessin, J. Shia, P. B. Paty, M. Weiser, L. K. F. Temple, B. D. Minsky, W. D. Wong, and J. G. Guillem A Pathologic Complete Response of Rectal Cancer to Preoperative Combined-Modality Therapy Results in Improved Oncological Outcome Compared With Those Who Achieve No Downstaging on the Basis of Preoperative Endorectal Ultrasonography Ann. Surg. Oncol., August 1, 2006; 13(8): 1047 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Glynne-Jones, S. Mawdsley, T. Pearce, and M. Buyse Alternative clinical end points in rectal cancer--are we getting closer? Ann. Onc., August 1, 2006; 17(8): 1239 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tulchinsky, M. Rabau, E. Shacham-Shemueli, G. Goldman, R. Geva, M. Inbar, J. M. Klausner, and A. Figer Can Rectal Cancers With Pathologic T0 After Neoadjuvant Chemoradiation (ypT0) Be Treated by Transanal Excision Alone? Ann. Surg. Oncol., March 1, 2006; 13(3): 347 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Kalff, C. Duong, E. G. Drummond, J. P. Matthews, and R. J. Hicks Findings on 18F-FDG PET Scans After Neoadjuvant Chemoradiation Provides Prognostic Stratification in Patients with Locally Advanced Rectal Carcinoma Subsequently Treated by Radical Surgery J. Nucl. Med., January 1, 2006; 47(1): 14 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Guillem, D. B. Chessin, J. Shia, H. G. Moore, M. Mazumdar, B. Bernard, P. B. Paty, L. Saltz, B. D. Minsky, M. R. Weiser, et al. Clinical Examination Following Preoperative Chemoradiation for Rectal Cancer Is Not a Reliable Surrogate End Point J. Clin. Oncol., May 20, 2005; 23(15): 3475 - 3479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. White, H. B. Xie, M. R. Gottfried, B. G. Czito, H. I. Hurwitz, M. A. Morse, G. C. Blobe, E. K. Paulson, J. Baillie, M. S. Branch, et al. Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer Ann. Surg. Oncol., March 1, 2005; 12(3): 214 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Stipa, A. Zernecke, H. G. Moore, B. D. Minsky, W. D. Wong, M. Weiser, P. B. Paty, J. Shia, and J. G. Guillem Residual Mesorectal Lymph Node Involvement Following Neoadjuvant Combined-Modality Therapy: Rationale for Radical Resection? Ann. Surg. Oncol., February 1, 2004; 11(2): 187 - 191. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
